# Obinutuzumab in Primary FSGS

> **NCT04983888** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Primary Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04983888
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-17
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983888, "Obinutuzumab in Primary FSGS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04983888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*